U.S. IPO Weekly Recap: Aktis Oncology Leads As First Sizable 2026 IPO

Group 1 - Three IPOs and five SPACs were priced this week, indicating a continued interest in public offerings [2] - Six IPOs and two SPACs submitted initial filings, suggesting a robust pipeline for upcoming market activity [2] - Aktis Oncology (AKTS) priced its upsized IPO, marking the first sizable deal of 2026 in the solid tumor biotech sector [2]